Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

DALT

From Wikipedia, the free encyclopedia
(Redirected from Diallyltryptamine)

DALT
Clinical data
Other namesN,N-Diallyltryptamine; DALT; DAT
Routes of
administration		Oral, intramuscular injection[1]
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: Analogue to a Schedule I/II drug (possibly)
  • UN: Unscheduled but not approved for human consumption.
  • in theory could be covered under similar analogue bills in other countries but this is not confirmed.
Identifiers
  • N-Allyl-N-[2-(1H-indol-3-yl)ethyl]prop-2-en-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H20N2
Molar mass240.350 g·mol−1
3D model (JSmol)
  • C=CCN(CC=C)CCc2c[nH]c1ccccc12
  • InChI=1S/C16H20N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h3-8,13,17H,1-2,9-12H2 checkY
  • Key:LQEATNFJCMVKAC-UHFFFAOYSA-N checkY
  (verify)

Diallyltryptamine (DALT), also known as N,N-diallyltryptamine, is a tryptamine derivative which has been identified as a designer drug.[2][3]

Use and effects

[edit]

According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), the dose of DALT is greater than 40 mg orally and its duration is unknown.[1] Its effects were not described.[1] Per Stephen Szara and colleagues in much earlier publications however, DALT and other extended N,N-dialkyltryptamines produce similar effects to dimethyltryptamine (DMT) but are longer-lasting, with durations of up to 3 hours.[1][4][5]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]
DALT activities
TargetAffinity (Ki, nM)
5-HT1A100
5-HT1B>10,000
5-HT1D689
5-HT1E378
5-HT1FND
5-HT2A701
5-HT2B61
5-HT2C385
5-HT3>10,000
5-HT4ND
5-HT5A>10,000
5-HT61,718
5-HT7>10,000
α1A1,663
α1B1,369
α1D>10,000
α2A124
α2B305
α2C901
β1–β3>10,000
D1, D2>10,000
D3672
D4, D5>10,000
H1127
H2–H4>10,000
M1–M5>10,000
I1ND
σ1101 (rat)
σ2356 (rat)
TAAR1Tooltip Trace amine-associated receptor 1ND
MORTooltip μ-Opioid receptor, DORTooltip δ-Opioid receptor>10,000
KORTooltip κ-Opioid receptor2,477
SERTTooltip Serotonin transporter150 (Ki)
NETTooltip Norepinephrine transporter1,121 (Ki)
DATTooltip Dopamine transporter1,406 (Ki)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:[6][7][8][9]

The receptor interactions of DALT have been studied.[6][7][8][9] The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[10]

Chemistry

[edit]

DALT has been used as an intermediate in the preparation of radiolabeled diethyltryptamine (DET).[11]

Synthesis

[edit]

The chemical synthesis of DALT has been described.[1]

Analogues

[edit]

Analogues of DALT include 4-HO-DALT, 4-AcO-DALT, 5-MeO-DALT, methylallyltryptamine (MALT), propylallyltryptamine (PALT), and isopropylallyltryptamine (iPALT), among others.[1]

History

[edit]

DALT was first described in the scientific literature by Stephen Szara and colleagues by 1962.[4][5]

Society and culture

[edit]
[edit]

Canada

[edit]

DALT is not an explicitly nor implicitly controlled substance in Canada as of 2025.[12]

United States

[edit]

DALT is not an explicitly controlled substance in the United States.[13] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  2. ↑ Michely JA, Helfer AG, Brandt SD, Meyer MR, Maurer HH (October 2015). "Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS" (PDF). Analytical and Bioanalytical Chemistry. 407 (25): 7831–42. doi:10.1007/s00216-015-8955-0. PMID 26297461. S2CID 26086597.
  3. ↑ Michely JA, Brandt SD, Meyer MR, Maurer HH (February 2017). "n, and LC-HR-MS/MS" (PDF). Analytical and Bioanalytical Chemistry. 409 (6): 1681–1695. doi:10.1007/s00216-016-0117-5. PMID 27933361. S2CID 206920201.
  4. 1 2 Brimblecombe RW, Pinder RM (1975). "Indolealkylamines and Related Compounds". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 98–144. ISBN 978-0-85608-011-1. OCLC 2176880. OL 4850660M. Other N,N-dialkyltryptamines produce similar effects to DMT in man, though their persistence is somewhat greater, with hallucinations lasting for up to 3 hours (Szara and Hearst, 1962). These include the N,N-diethyl (DET, 4.8), N,N-dipropyl (4.9), and N,N-diallyl (4.10) compounds, none of which are found in nature.
  5. 1 2 Szara S, Hearst E (1962). "The 6-Hydroxylation of Tryptamine Derivatives: A Way of Producing Psychoactive Metabolites". Annals of the New York Academy of Sciences. 96 (1): 134–141. Bibcode:1962NYASA..96..134S. doi:10.1111/j.1749-6632.1962.tb50108.x. The dipropyl and diallyl derivatives have similar hallucinogenic activity in man, as we found recently.
  6. 1 2 "Kᵢ Database". PDSP. 28 March 2025. Retrieved 28 March 2025.
  7. 1 2 Liu T (2016). "BindingDB BDBM50140058 CHEMBL3752576". Bioorganic & Medicinal Chemistry Letters. 26 (3): 959–964. doi:10.1016/j.bmcl.2015.12.053. PMID 26739781. Retrieved 28 March 2025.
  8. 1 2 Cozzi NV, Daley PF (February 2016). "Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines" (PDF). Bioorganic & Medicinal Chemistry Letters. 26 (3): 959–964. doi:10.1016/j.bmcl.2015.12.053. PMID 26739781.
  9. 1 2 Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL (November 2018). "Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs" (PDF). Neuropharmacology. 142: 231–239. doi:10.1016/j.neuropharm.2018.02.028. PMC 6230509. PMID 29499272.
  10. ↑ Halberstadt AL, Geyer MA (2018). "Effect of Hallucinogens on Unconditioned Behavior". Behavioral Neurobiology of Psychedelic Drugs. Curr Top Behav Neurosci. Vol. 36. pp. 159–199. doi:10.1007/7854_2016_466. ISBN 978-3-662-55878-2. PMC 5787039. PMID 28224459. The HTR has also been observed in rodents treated with N-methyl-N-ethyltryptamine (MET), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-diisopropyltryptamine (DIPT), and N,N-diallyltryptamine (DALT) (Fantegrossi et al. 2008; Smith et al. 2014; Carbonaro et al. 2015; Halberstadt and Klein, unpublished observations).
  11. ↑ Brandt SD, Tirunarayanapuram SS, Freeman S, Dempster N, Barker SA, Daley PF, et al. (2008). "Microwave-accelerated synthesis of psychoactive deuterated N,N-dialkylated-[α,α,β,β-d4]-tryptamines". Journal of Labelled Compounds and Radiopharmaceuticals. 51 (14): 423–429. doi:10.1002/jlcr.1557.
  12. ↑ "Controlled Drugs and Substances Act". Department of Justice Canada. 5 December 2025. Retrieved 20 January 2026.
  13. ↑ Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=DALT&oldid=1363809128"